source
- Create Medicines secures $122M Series B to advance in vivo CAR-T therapiesCreate Medicines, a Cambridge biotech, announced a $122 million Series B financing to expand its in vivo CAR-T cell therapy platform targeting cancer and autoimmune diseases. The round was co-led…
- BeOne Medicines receives accelerated FDA approval for sonrotoclax in mantle cell lymphomaBeOne Medicines announced that the U.S. Food and Drug Administration granted accelerated approval to its BCL2 inhibitor sonrotoclax for treatment of mantle cell lymphoma. The approval is based on…